Expert Directory
Robert Lanford, PhD
Dir. of Southwest National Primate Research Center
Texas Biomedical Research InstituteHepatitis, Primate Research, Liver Disease
Dr. Robert Lanford, PhD, is currently the Director of the Southwest National Primate Research Center, one of seven NIH National Primate Research Centers. He is a Scientist at the Texas Biomedical Research Institute and an Adjunct Professor at the University of Texas Health Science Center. Dr. Robert E. Lanford received a B.S. degree from the University of Texas at Arlington in 1974 and a Ph.D. in Virology from Baylor College of Medicine in 1979. He served as Assistant Professor at Baylor College of Medicine until 1984 when he moved to the Southwest Foundation for Biomedical Research (now Texas Biomedical Research Institute) to initiate programs on the use of nonhuman primates as models for human hepatitis infections. Dr. Lanford has published over 170 scientific papers and serves as a reviewer for several journals. His laboratory performs research on multiple hepatitis viruses HAV, HBV, HCV and GBV-B. One of the primary goals of his research program is to better understand the interactions of the virus with the host, and how these interactions influence either viral clearance or persistence and disease progression. His studies in the chimpanzee were the first to use total genome microarray analysis to examine viral-host interactions and the innate immune response to HCV. In collaboration with pharmaceutical companies, he has utilized the chimpanzee model of chronic HBV and HCV infections to evaluate efficacy of new antiviral therapies as the last preclinical step prior to human clinical trials. These studies contributed to the development of cocktails of antivirals that can now cure HCV infection in 12 weeks. Recently, Dr. Lanford has developed a primate model for liver cancer by the genetic engineering of primary baboon hepatocytes with activated baboon oncogenes and autologous transplantation of the cells to the liver of the immunocompetent hepatocyte donor. Efforts are ongoing in his laboratory to develop new nonhuman primate models for HBV research.
Suzette Tardif, PhD
Scientist and Associate Dir. of Primate Research
Texas Biomedical Research Institutezika, Reproductive Biology, Aging, Obesity
Dr. Tardif is Associate Director of Research and Senior Management Team member for SNPRC and has extensive experience coordinating large, integrated research projects throughout her professional career. She served as the marmoset expert for the team charged with sequencing the marmoset genome and as the species expert for recent studies on development of induced pluripotent stem cell (iPS cell) technologies. Her research is focused on metabolism, behavior and reproduction and, most recently, on the characterization of the marmoset as a model for obesity and aging. Dr. Tardif has more than 30 years of expertise in the development of common marmoset monkeys as biomedical models in diverse areas including: Reproductive biology Infectious disease Neuroscience Aging and obesity
Marcel Daadi, PhD
Leader of SNPRC Regenerative Medicine & Aging Unit
Texas Biomedical Research InstituteRegenerative Medicine, Stroke, Parkinson's Disease, Translational Research
Dr. Daadi is an expert in regulated translational research and has developed therapeutic neural stem cell lines (NSC) for clinical use in Parkinson’s disease, stroke, and to target brain tumors in both industrial and academic settings. He discovered a novel technique of engineering these stem cell lines from pluripotent human embryonic stem cells and continues to develop this therapeutic cell line for clinical use. Dr. Daadi came to Texas Biomed in 2014 and is the team leader for the SNPRC Regenerative Medicine and Aging research unit. Results from his studies are the foundation of translational research and help to repair diseased or injured brain through transplantation of highly purified NSCs and stimulation of internal repair mechanisms.
Marie-Claire Gauduin, PhD
Assoc. Scientist, Virology & Immunology
Texas Biomedical Research InstituteHIV, AIDS
Dr. Gauduin has more than 25 years of experience in HIV/AIDS research and medical microbiology. She has been working extensively on HIV and the development of novel vaccine strategies using the non-human primate model for AIDS. In her work, she uses epithelial stem cells and weakened recombinant papillomavirus as vaccine- vectors to protect against multiple low-dose mucosal challenges. Dr. Gauduin is also developing a neonatal model for tuberculosis to study HIV/TB co-infection in pediatric AIDS. Her specific research interests are: Early events of simian immunodeficiency virus (SIV) transmission in a macaque model Host immune responses to infectious diseases Early virus-specific T cell responses in neonates Tuberculosis/SIV coinfection in pediatric AIDS
Animal Behavior, Veterinarian
Dr. Bernal oversees all aspects of the SNPRC animal care and use program. He has more than 36 years of experience in laboratory animal care and medicine. To increase the number of certified laboratory animal technicians at Texas Biomed and other institutions, he has developed institution-wide training and certification programs. Dr. Bernal has been integral to developing the SNPRC study process manual that details all of the steps required to complete a study from start to finish. Dr. Bernal oversees and develops standard operating procedures for: Comprehensive socialization and environmental enrichment plan Preventative medicine program (frequent physicals, TB testing, parasite evaluation, viral testing) Veterinary care program Aseptic technique Management of pain and distress Animal enclosure sanitation.
Ebola, zika, Biodefense, Biocontainment, biocontainment lab, Biocontainment Laboratory
Dr. Patterson’s laboratory works on the development of countermeasures against potential biological weapons. Her group focuses on the development of therapies and vaccines against naturally occurring pathogens that can cause sporadic but lethal outbreaks, and her most recent studies concentrate on hemorrhagic fever viruses. Dr. Patterson has been involved in the development of three vaccines against Ebola and two vaccines against Lassa fever that are undergoing further studies. Her lab utilizes the maximum containment laboratory (BSL-4) at Texas Biomed. Dr. Patterson helped develop a marmoset model used for multiple infectious agents: Ebola virus Marburg virus Lassa fever Eastern Equine Encephalitis virus
Cancer, Epidemology, Cancer Prevention, Breast Cancer, Health Disparities
Cancer, Breast Cancer Screening, Radiology, Mammography, breast cancer early detection, Breast Cancer, Breast Imaging, breast biopsy, Diagnostic Imaging, diagnostic radiology
Breast Cancer, Breast Cancer Surgery, Surgery, cancer incidence, Health Care Delivery, Health Care Outcomes
Neurosurgery, Glioblastoma, Brain Cancer, immunotheraphy, Cancer Vaccines
Cancer Genetics, Cancer Therapies, Drug Discovery, Radiation effects
Robotic Surgery, Bladder Cancer, Prostate Cancer, Cancer
Tobacco, Tobacco Control, tobacco policy, Epidemiologic, Public Health, e-cigarretes, vaping
Cancer, Cancer Research, Vitamin D, immunotheraphy, Cancer Vaccines, Genomics, Personalized Medicine, Cancer Therapies, Medical Research
Pediatric Cancer, Hodgkin Lymphoma, pediatric leukemia, Cancer Therapies
Liver Cancer, Pancreatic, Cancer, Pancreatic Cancer, abdominal cancer , Gastrointestinal Cancer, Stomach Cancer, Gallbladder Cancer
Martin Mahoney, MD
Chair of the Department of Clinical Prevention
Roswell Park Comprehensive Cancer CenterFamily Medicine, Primary Care, Preventive Medicine, Health Behavior, Lung Cancer, Smoking Cessation, HPV, Vaccination
Bone Marrow, Bone Marrow Transplant, Leukemia, Lymphoma, Multiple Myeloma, Cancer, Blood Cancer, hematologic oncology
Carl Morrison, MD
Executive Director of the Center for Personalized
Roswell Park Comprehensive Cancer CenterGenomics, Personalized Medicine, molecular pathology, Cancer, Cancer Genetics, Molecular Diagnostics, Medical Diagnostics
Dr. Carl D. Morrison joined the faculty of Roswell Park Comprehensive Cancer Center in January 2007, and is currently the Senior Vice President of Scientific Development and Integrative Medicine; Director of the Pathology Resource Network; Clinical Chief, Department of Pathology & Laboratory Medicine; Director, Division of Molecular Pathology, and Professor of Oncology. Prior to coming to Roswell Park, Dr. Morrison spent five years as faculty at The Ohio State University Medical Center after completing his residency there in Anatomic Pathology. Dr. Morrison is a board-certified pathologist with a Certificate of Qualification in Oncology in NYS who has an interest in both clinical and research areas. As Senior Vice President of Scientific Development and Integrative Medicine, Dr. Morrison supports the development of new core capabilities and technology platforms in order to conduct highly integrative research across both the basic sciences and clinical care. Dr. Morrison continues to lead the Pathology Resource Network (PRN) at Roswell Park. The overall goal of the PRN is to facilitate access to human biospecimens for IRB-approved investigators with an emphasis on translational efforts. The services offered are quite diverse and serve a unique link between the research and clinical arena. Dr. Morrison started and previously directed the Clinical Data Network (CDN) at Roswell Park. The CDN is the organization of clinical data for research purposes utilizing a federated database approach. The primary goal of the CDN is the promotion of translational research at Roswell Park in a non-human subject research setting.
Igor Puzanov, MD
Director of Early Phase Clinical Trials Program an
Roswell Park Comprehensive Cancer CenterNovel Therapies, Melanoma, immunotheraphy, Cancer Vaccines, Personalized Medicine, Cancer
His role as a Clinical Professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Professor of Medicine and Director of Early Phase Clinical Trials Program in the Department of Medicine at Roswell Park Comprehensive Cancer Center, He is developing novel therapies for patients with cancer. This includes clinical trials from the early pre-clinical phase through phase I/II/III with emphasis on a combination of immune and targeted agents, novel drug design, including histology-agnostic trial development of targeted therapies. He also provides advice on regulatory requirements and necessary steps associated with advancing drugs, devices, and imaging agents toward clinical trials in patients. In his professional career, I have focused both on developing precision medicine agents as well as immunotherapies. In the first-in-human trial of PLX4032/vemurafenib, our team has provided critical PK/PD data that led to the first in class/ first in human FDA-approved BRAF inhibitor. His interest and expertise in immunotherapy started in the early 1990s with animal models of IL-2 and IL-15 cytokines and natural killer cell development, continued with high dose IL-2 studies, and subsequently Phase I-III trials with both CTLA-4 and PD1/PDL-1 checkpoint inhibitors. Our team was instrumental in the development of talimogene laherparepvec, the first in human oncolytic virus therapy for patients with melanoma. Recently, we have explored immunotherapy combinations with targeted agents as well as combinations of oncolytic viruses with checkpoint inhibitors. Our work was instrumental in several FDA approvals of breakthrough anti-cancer drugs (vemurafenib, dabrafenib+trametinib, vemurafenib+cobimetinib, pembrolizumab, talimogene laherparepvec) and resulted in almost 100 manuscripts, including New England Journal of Medicine, Lancet, Journal of Clinical Oncology, JAMA, Nature. I am a member of American Society of Medical Oncology, Society of Immunotherapy in Cancer, ACP, AACR and Society of Melanoma Research and serve as an editor and reviewer for several peer reviewed journals.
Please enter your username and
password to login
close
-
News keyboard_arrow_right
Latest News Coronavirus News Currently Embargoed News Research News Releases Google Fact Check Research Alert Preprints Marketplace News with Video/Audio Multimedia
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right